Jagsonpal Pharmaceuticals Limited

JAGSNPHARM

INE048B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:47:54 21/06/2024 BST			5-day change	1st Jan Change
339.8 ^INR	+0.50%		-1.26%	-12.61%

05-24	Jagsonpal Launches Drug for Vasomotor Symptoms; Shares Jump 5%	MT
05-24	Jagsonpal Launches Memup India's First Bioidentical Hormone Replacement Therapy in A Single Pill	CI

Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2024

May 20, 2024 at 02:46 pm

Jagsonpal Pharmaceuticals Limited at its board meeting held on May 20, 2024, the Board recommended a dividend of INR 5 (100%) per equity share for the financial year ended March 31, 2024 subject to approval in AGM.

Latest news about Jagsonpal Pharmaceuticals Limited

Jagsonpal Launches Drug for Vasomotor Symptoms; Shares Jump 5%	05-24	MT
Jagsonpal Launches Memup India's First Bioidentical Hormone Replacement Therapy in A Single Pill	05-24	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-20	CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2024	05-20	CI
Jagsonpal Pharmaceuticals Limited agreed to acquire India & Bhutan business of Yash Pharma Laboratories Private Limited from Yash Pharma Laboratories Private Limited for approximately INR 930 million.	05-15	CI
Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®	03-08	CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes	02-02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-03	CI
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1	03/08/23	MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	02/08/23	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23/05/23	CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23/05/23	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar.	30/03/23	CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer	13/02/23	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	08/02/23	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	31/12/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	16/07/22	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm cancelled the acquisition of 26% stake in Jagsonpal Pharmaceuticals Limited.	19/06/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Infinity Holdings to Acquire Controlling Stake in Jagsonpal Pharmaceuticals for $36 Million	22/02/22	MT
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others entered into a share purchase agreement to acquire 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar for INR 2.7 billion.	20/02/22	CI
Infinity Investment Management made an offer to acquire 26% stake in Jagsonpal Pharmaceuticals Limited for INR 1.6 billion.	20/02/22	CI

Chart Jagsonpal Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Companyâs therapy areas include gynecology, orthopedics, and others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JAGSONPAL PHARMACEUTICALS LIMITED	-12.61%	108M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B